Chemical Enhancers in Buccal and Sublingual Delivery
DOI:
https://doi.org/10.37285/ijpsn.2011.4.1.3Abstract
Rapid developments in the field of molecular biology and gene technology resulted in generation of many macromolecular drugs with superior pharmacological efficacy, site specificity and devoid of toxic effects. However, the major problem for the oral delivery of these therapeutic agents is their extensive presystemic metabolism, instability in acidic environment resulting into inadequate and erratic oral absorption. Parenteral route of administration is the only established route that overcomes all these drawbacks associated with these orally less/inefficient drugs. But, these formulations are costly, have least patient compliance and require repeated administration. The buccal delivery system found to be most convenient and easily accessible site for the delivery of such therapeutic agents. This route provides direct access to the systemic circulation through the internal jugular vein thus avoiding the hepatic first-pass effect and degradation in the gastrointestinal tract, ease of administration, and the ability to terminate delivery when required. The epithelium that lines the oral mucosa is a very effective barrier that restricts the membrane permeation for many drugs administered via this route, and can be a limiting factor to the absorption of drugs. The use of penetration enhancers is one approach for improving buccal drug delivery. This requisite has fostered the study of penetration enhancers that will safely alter the permeability restrictions of the buccal mucosa. This review describes various classes of transmucosal chemical permeation enhancers such as bile salts, surfactants, fatty acids and their derivatives, chelators, cyclodextrins and chitosan along with their mechanism of action. Even though these enhancers influence drug delivery, further exploration of these compounds is required to understand their modifying action on the properties of buccal mucosa.
Downloads
Metrics
Keywords:
Molecular biology, pre systemic metabolism, buccal delivery, penetration enhancer, bile salts, chitosan
Downloads
Published
How to Cite
Issue
Section
References
Amir H Shojaei. Buccal Mucosa as A Route for Systemic Drug Delivery: A Review. J Pharm. Pharmaceut. Sci. 1 (1): 15-30 (1998).
Aungst A. Permeability and metabolism as barriers to transmucosal delivery of peptides and proteins. In D.S.Hsieh (Ed.), Drug Permeation Enhancement. Theory and Applications, Marcel Dekker, New York, 1994, pp. 323-343.
Aungst BJ, Rogers NJ, Shefter E. Comparison of nasal, rectal, buccal, sublingual and intramuscolar insulin efficacy and the effects of a bile salts absorption promoter. J. Pharmacol. Exp. Ther. 244: 23-7 (1988).
Aungst BJ. Oral mucosal permeation enhancement: possibilities and limitations, In Rathbone MJ(Ed.), Oral Mucosal Drug Delivery, Marcel Dekker, New York, 1996, pp. 65–83.
Aungst BJ. Site-dependence and structure-effect relationships for alkyl glycosides as transmucosal absorption promoters for insulin. Int. J Pharm. 105: 219-25 (1994).
Bendas B, Schmalfub U, and Nuebert R. Influence of propylene glycol as cosolvent on mechanism of drug transport from hydrogels. Int. J Pharm. 116:19 (1995).
Bernkop-Schnurch A. Chitosan and its derivatives: potential excipients for peroral peptide delivery systems. Int. J Pharm. 194: 1-13 (2000).
Ceschel GC et al., In-vitro permeation through porcine buccal mucosa of Salvia desoleana Atzei & Picci essential oil from topical formulations. Int. J Pharm. 195: 171 (2000).
Coutel-Egros A, Maitani Y, Veillard M, Machida Y, Nagai T. Combined effects of pH, cosolvent and penetration enhancers on the in-vitro buccal absorption of propranolol through excised hamster cheek pouch. Int. J. Pharm. 84: 117–128 (1992).
Ebert CD, Heiber SJ, Dave SC et al., Mucosal delivery of macromolecules. J. Control Release 28: 37-44 (1994).
Gandhi R and Robinson J. Mechanisms of penetration enhancement for transbuccal delivery of salicylic acid. Int. J. Pharm. 85: 129-140 (1992).
Gandhi RB, Robinson JR. Oral cavity as a site for bioadhesive drug delivery. Adv. Drug Deliv. Rev. 13: 43–74 (1994).
Ganem A, Falson R, Buri P. Eur. J. Drug Metab. Pharmacokinet. 111: 112–123 (1996).
Ganem-Quintanar A, Kalia YN, Falson-Rieg F, et al., Mechanisms of oral permeation enhancement, Int. J. Pharm. 155: 127-42 (1997).
Hadgraft J, Peck J, William DG, et al., Mechanism of action of skin penetration enhancers/retarders: azone and analogues. Int. J. Pharm. 141: 17-25 (1996).
Hao J, Heng PSW. Buccal delivery systems. Drug Dev. Ind. Pharm. 29: 821-32 (2003).
Harris D, Robinson JR. Drug delivery via the mucous membranes of the oral cavity. J. Pharm. Sci. 81: 1 –10 (1992).
Hoogstraate AJ et al., Effects of the penetration enhancer glycodeoxycholate on the lipid integrity in porcine buccal epithelium in-vitro. Eur. J. Pharm. Sci. 5: 189 (1997).
Hoogstraate AJ, Senel S, Cullander C, Verhoef J, Junginger HE, and Bodde HE. Effects of bile salts on transport rates and routes of FTIC-labelled compounds across porcine buccal epithelium in-vitro. J. Control. Rel. 40: 211-221 (1996).
Hoogstraate AJ, Verhoef JC, Tuk B, Pijpers A, van leengoed LAMG, Vheijden JHM, Junjinger HE, and Bodde HE. Buccal delivery of fluorescein isothiocyanate-dextran 4400 and the peptide drug buserelin with glycodeoxycholate as an absorption enhancer in pigs. J. Control. Rel. 41: 77-84 (1996).
Hoogstraate JA, Verhoef JC, Pijpers A et al., In-vivo buccal delivery of peptidedrug buserelin with glycodeoxycholate as an absorption enhancer in pigs. Pharm. Res. 13: 1233-7 (1996).
Howie NM, Trigkas TK, Cruchley AT, Wertz PW, Squier CA, Williams DM. Short-term exposure to alcohol increases the permeability of human oral mucosa. Oral Dis. 7: 349– 354 (2001).
Joseph A. Nicolazzo and Barrie C. Finnin. In-vivo and In-vitro Models for Assessing Drug Absorption across the Buccal Mucosa. In Carsten Ehrhardt and Kwang-Jin Kim (Eds.), Drug Absorption Studies In Situ, In-vitro and In Silico Model, AAPS Press, New York, 2007, pp. 89-111.
Jun X, Xiaoling F, and Xiaoling L. Transbuccal delivery of 2’,3’-dideoxycytidine: In-vitro permeation study and histological investigation. Int J Pharm 231: 57 (2002).
Junginger H, Hoogstraate J, and Verhoef J. Recent advances in buccal drug delivery and absorption in-vitro and in-vivo studies. J. Control Release 62: 149 (1999).
Kitano M et al., Buccal absorption through golden hamster cheek pouch in-vitro and in-vivo of 17-estradiol from hydrogels containing three types of absorption enhancers. Int. J. Pharm. 174: 19 (1998).
Kremer MJ, Senel S, Kas SH, Wertz PW, Hincal AA, Squier CA. Oral mucosal drug delivery: chitosan as vehicle and permeabilizer. J. Dent. Res. 77: 718 (1999).
Kurosaki Y and Kimura T. Regional variation in oral mucosal drug permeability. Crit. Rev. Ther. Drug. Carrier Syst. 17: 467 (2002).
Kurosaki Y, Hisaichi SI, Hong LZ, Nakayama T, Kimura T. Enhanced permeability of keratinized oral-mucosa to salicylic acid with 1-dodecylazacycloheptan-2-one (Azone): in-vitro studies in hamster cheek pouch. Int. J. Pharm. 49: 47– 55 (1989).
Lee J and Kellaway IW. Buccal permeation of [D-Ala(2), D-Leu(5)]enkephalin from liquid crystalline phases of glyceryl monooleate. Int. J. Pharm. 195: 35 (2000).
Morgan TM, O’Sullivan HM, Reed BL et al., Transdermal delivery of estradiol in postmenopausal women with a novel topical aerosol. J. Pharm. Sci. 87: 1226-8 (1998).
Morishita M et al., Pluronic F-127 gels incorporating highly purified unsaturated fatty acids for buccal delivery of insulin. Int. J. Pharm. 212: 289 (2001).
Nicolazzo JA, Reed BL, Finnin BC. Assessment of the effects of sodium dodecyl sulfate on the buccal permeability of caffeine and estradiol. J. Pharm. Sci. 93: 431–440 (2004).
Nicolazzo JA, Reed BL, Finnin BC. Modification of buccal drug delivery following pretreatment with skin penetration enhancers. J. Pharm. Sci. 93: 2054–2063 (2004).
Ogiso T, Iwaki M and Paku T. Effect of various enhancers on transdermal penetration of indomethacin and urea, and relationship between penetration parameters and enhancement factors. J. Pharm. Sci. 84: 482 (1995).
Oh CK and RitschelWA. Biopharmaceutic aspects of buccal absorption of insulin. Exp. Clin. Pharmacol. 12: 205 (1990).
Pillai O, Nair V, Panchagnula R. Transdermal iontophoresis of insulin: IV. Influence of chemical enhancers. Int. J. Pharm. 269: 109– 120 (2004).
Portero A, Remunan-Lopez C and Nielsen HM. The potential of chitosan in enhancing peptide and protein absorption across the TR146 cell culture model—an in-vitro model of the buccal epithelium. Pharm. Res. 19: 169 (2002).
Punitha S, Girish Y. Polymers in mucoadhesive buccal drug delivery system – A review. Int. J. Res. Pharm. Sci. 1(2): 170-186 (2010).
Quintanar A et al., Ex vivo oral mucosal permeation of lidocaine hydrochloride with sucrose fatty acid esters as absorption enhancers. Int. J. Pharm. 173: 203 (1998).
Quintanar A et al., Mechanisms of oral permeation enhancement. Int. J. Pharm. 156: 127 (1997).
Sandri G, Rossi S, Ferrari F et al., Assessment of chitosan derivatives as buccal and vaginal penetration enhancers. Eur. J. Pharm. Sci. 21: 351-9 (2004).
Sayani AP, Chien YW. Systemic delivery of peptides and proteins across absorptive mucosae. Crit. Rev. Ther. Drug Carrier Syst. 13 (1, 2): 85-184 (1996).
Senel S and Hincal AA. Drug permeation enhancement via buccal route: Possibilities and limitations. J. Control Release 72: 133 (2001).
Senel S, Hoogstraate AJ, Spies F, Verhoef JC, Bos-van Geest A, Junginger HE and Bodde HE, Enhancement of in-vitro permeability of porcine buccal mucosa by bile salts: kinetic and histological studies. J.Control. Rel. 32: 45-56 (1994).
Senel S, Kremer MJ, Kas S, Wertz PW, Hincal AA, Squier CA. Enhancing effect of chitosan on peptide drug delivery across buccal mucosa. Biomaterials 21: 2067– 2071 (2000).
Shin S and Kim J. Enhanced permeation of triamcinolone acetonide through the buccal mucosa. Eur. J. Pharm. Biopharm 50: 217 (2000).
Shin S, Bum J, and Choi J. Enhanced bioavailability by buccal administration of triamcinolone acetonide from the bioadhesive gels in rabbits. Int. J. Pharm. 209: 37 (2000).
Shojaei AH, Li X. Determination of transport route of acyclovir across buccal mucosa. Proc. Int. Symp. Control. Release Bioact. Mater. 24: 427–428 (1997).
Silvia Rossi, Giuseppina Sandri, Carla Caramella. Buccal Delivery Systems for Peptides. Am. J. Drug Deliv. 3(4): 215-225 (2005).
Song Y et al., Mucosal drug delivery: Membranes, methodologies and applications. Crit. Rev. Ther. Drug Carrier Syst. 21(3): 195–256 (2004).
Sreenivas SA and Pai KV. Thiolated Chitosans: Novel Polymers for Mucoadhesive Drug Delivery – A Review. Tropical Journal of Pharmaceutical Research 7 (3): 1077-1088 (2008).
Steward A, Bayley DL, Howes C. The effect of enhancers on the buccal absorptionof hydrid (BDBB) alpha-interferon. Int. J. Pharm. 104: 145-9 (1994).
Tengamnuay P, Sahamethapat A, Sailasuta A, et al., Chitosan as nasal absorption enhancers of peptides: comparison between free amine chitosans and soluble salts. Int. J. Pharm. 197: 53-67 (2000).
Tsutsumi K, Obata Y, Takayama K, Loftsson T, Nagai T. Effect of cod-liver oil extract on the buccal permeation of ergotamine tartrate. Drug Dev. Ind. Pharm. 24: 757– 762 (1998).
Turunen TM, Urtti A, Paronen P, Audus KL, Rytting JH. Effect of some penetration enhancers on epithelial membrane lipid domains: evidence from fluorescence spectroscopy studies. Pharm. Res. 11: 288–294 (1994).
Veuillez F, Kalia YN, Jacques Y, Deshusses J, Buri, P. Comparison of ex-vivo oralmucosal permeation of tryptophan-leucine (Trp-leu) and its myristoyl derivative. Int. J. Pharm. 170: 85-91 (1998).
Veuillez F, Kalia YN, Jacques Y, Deshusses, J.; Buri, P. Factors and strategies for improving buccalabsorption of peptides. Eur. J. Pharm. Biopharm. 51: 93-109 (2001).
Xiang J, Fang X, Li X. Transbuccal delivery of 2', 3' dideoxycytidine: in-vitro permeation study and histological investigation. Int. J. Pharm. 231: 57– 66 (2002).
Yajaman Sudhakar, Ketousetuo Kuotsu, Bandyopadhyay AK. Buccal bioadhesive drug delivery -A promising option for orally less efficient drugs. Journal of Controlled Release 114: 15–40 (2006).
Yamamoto A et al., Absorption of water soluble compounds with different molecular weights and [ASU1.7]-eel calcitonin from various mucosal administration sites. J. Control Release 76: 363 (2001).
Zhang J, Niu S, Ebert C et al., An in-vivo dog model for studying recovery kinetics of buccal mucosa permeation barrier after exposure to permeation enhancers: apparent evidence of effective enhancement without tissue damage. Int. J. Pharm. 101: 15-22 (1994).
